VIOXX® (rofecoxib) Information Center

Merck & Co., Inc.

VIOXX® (rofecoxib) Information Center

The information set forth in the documents posted on this page was factually accurate on the date it was issued. While this information remains on Merck's Web site, the company assumes no duty to update the information to reflect subsequent developments. Consequently, readers of this information should not rely on it as current or accurate after the issuance dates.

LITIGATION INFORMATION

22 Oct 2009	The Supreme Court of Canada Will Not Review the Saskatchewan Court of Appeal Judgment Overturning a Class Certification Order in VIOXX® Action
13 May 2009	Merck Statement on Missouri Court of Appeals Decision Affirming a Ruling Certifying a Class of Missouri Plaintiffs Seeking Out-of-Pocket VIOXX® Costs
11 May 2009	Ontario Court Grants Merck Time to Appeal Class Certification of Vioxx Action

Scientific Information

25 July 2007	Statement Regarding the Publications of Two VIOXX® Studies: The ViP Trial in Current Medical Research and Opinion and The VICTOR Trial in the New England Journal of Medicine ( PDF* 22KB)
03 July 2007	VIOXX® Update: Statement on VICTOR Study ( PDF* 22KB)
12 Sep 2006	Merck Statement about COX-2 Inhibitor Review Studies in the Journal of the American Medical Association ( PDF* 23KB)

COMPANY STATEMENTS

30 April 2009	Merck Responds to Questions about the Australasian Journal of Bone and Joint Medicine Journal ( PDF* 18KB)
06 Sep 2006	Report of The Honorable John S. Martin, Jr. to the Special Committee of the Board of Directors of Merck & Co., Inc. Concerning the Conduct of Senior Management in the Development and Marketing of VIOXX®
06 Sep 2006	Statement on the Martin Report by William G. Bowen ( PDF* 8KB)